Immunomedics, Inc. (IMMU) is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company's technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Its product candidates include 90Y-clivatuzumab tetraxetan. Its radiolabeled antibody is in a Phase III registration trial in patients with advanced pancreatic cancer. Its portfolio of investigational products also includes antibody-drug conjugates (ADCs). Its ADCs consist of sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials for a number of solid tumors and metastatic colorectal cancer (mCRC), respectively. It has other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in clinical and pre-clinical development-stages.
Immunomedics Breast Cancer Drug Kicked Out of Prestigious ASCO Cancer Conference Immunomedics was caught trying to sneak old, previously presented clinical data on its triple-negative breast cancer drug IMMU-132 into the American Society of Clinical Oncology (ASCO) annual meeting. Read full article here: https://www.thestreet.com/story/135...it&utm_medium=organic&utm_campaign=stocktwits
found it ... so there is already an IMMU thread ...... it needs update good climb since Tormented opened this thread 4-5 $ up my good scalping stock
few of latest news Jun-01-17 08:00AM Immunomedics to Present at Jefferies 2017 Global Healthcare Conference GlobeNewswire May-26-17 09:33AM Biotech Movers: Immunomedics, Aerie, Exelixis TheStreet.com May-25-17 12:41PM ETFs with exposure to Immunomedics, Inc. : May 25, 2017 Capital Cube May-24-17 09:51AM Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q3, 2017 By the Numbers : May 24, 2017 Capital Cube May-18-17 05:00AM Edited Transcript of IMMU earnings conference call or presentation 10-May-17 9:00pm GMT Thomson Reuters StreetEvents May-11-17 09:21PM Edited Transcript of IMMU earnings conference call or presentation 10-May-17 9:00pm GMT Thomson Reuters StreetEvents +6.14% May-10-17 04:10PM Immunomedics reports 3Q loss Associated PressMMU did the 52 wk high 8.08
yesterday did the 52 wk high 8.08 Immunomedics, Inc. (IMMU) 7.88+0.30 (+3.96%) At close: June 2 4:00PM EDT Day's Range 7.48 - 8.08 52 Week Range 1.95 - 8.08 Volume 2,611,023 Avg. Volume 3,387,073
Hey all, I picked this stock up a little while ago. Started looking into it a little more deeply recently and decided to make this quick review video: Let me know what you think! Also, I'm open to suggestions if you'd like to see other videos like this one! Thanks!
